Apellis Pharmaceuticals Announces Board and Executive Changes
Ticker: APLS · Form: 8-K · Filed: Apr 21, 2025 · CIK: 1492422
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: APLS
TL;DR
Apellis Pharma (APLS) filing shows board shakeup and exec pay changes.
AI Summary
On April 17, 2025, Apellis Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a departure of directors or certain officers, the election of new directors, and updates to compensatory arrangements for certain officers. Specific details regarding the individuals involved and the nature of the compensation changes were not elaborated upon in the provided text.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy, governance, or financial outlook, potentially impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can sometimes precede significant strategic shifts or indicate internal dynamics that may affect future performance.
Key Numbers
- 001-38276 — SEC File Number (Identifies the company's filing history with the SEC.)
- 27-1537290 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Waltham, MA (location) — Principal Executive Offices
FAQ
What specific changes were made to the board of directors of Apellis Pharmaceuticals, Inc. on or around April 17, 2025?
The filing indicates the departure of directors and the election of new directors, but does not specify names or exact dates of these changes within the provided text.
Were there any changes to the executive officers of Apellis Pharmaceuticals, Inc. reported in this 8-K?
The filing mentions 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', suggesting potential changes among executive ranks.
What is the nature of the 'Compensatory Arrangements of Certain Officers' mentioned in the filing?
The filing states that there were updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not provided in the excerpt.
What is the principal business address of Apellis Pharmaceuticals, Inc.?
The principal executive offices are located at 100 Fifth Avenue, Waltham, MA 02451.
What is the earliest event date reported in this Form 8-K?
The earliest event date reported is April 17, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 21, 2025 regarding Apellis Pharmaceuticals, Inc. (APLS).